Trial Profile
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer (Genentech Inc.DST4964g)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandortuzumab vedotin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 05 Nov 2019 Results assessing safety and efficacy of DSTP3086S in patients with metastatic castration-resistant prostate cancer, published in the Journal of Clinical Oncology
- 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development: 2017 Annual Meeting of the American College of Clinical Pharmacology.
- 05 Sep 2016 Status changed from recruiting to completed.